262 related articles for article (PubMed ID: 22569819)
1. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin.
Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant C; Bowles DW; George B; Wen X; Aleksunes LM; Joy MS
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640195
[TBL] [Abstract][Full Text] [Related]
3. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms.
Meyer zu Schwabedissen HE; Verstuyft C; Kroemer HK; Becquemont L; Kim RB
Am J Physiol Renal Physiol; 2010 Apr; 298(4):F997-F1005. PubMed ID: 20053795
[TBL] [Abstract][Full Text] [Related]
4. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
5. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
[TBL] [Abstract][Full Text] [Related]
7. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
[TBL] [Abstract][Full Text] [Related]
8. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
Filipski KK; Mathijssen RH; Mikkelsen TS; Schinkel AH; Sparreboom A
Clin Pharmacol Ther; 2009 Oct; 86(4):396-402. PubMed ID: 19625999
[TBL] [Abstract][Full Text] [Related]
9. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
10. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
Cho SK; Chung JY
Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
[TBL] [Abstract][Full Text] [Related]
12. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
13. Clinical Aspects of Drug-Drug Interaction and Drug Nephrotoxicity at Renal Organic Cation Transporters 2 (OCT2) and Multidrug and Toxin Exclusion 1, and 2-K (MATE1/MATE2-K).
Saad AAA; Zhang F; Mohammed EAH; Wu X
Biol Pharm Bull; 2022; 45(4):382-393. PubMed ID: 35370262
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
15. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
[TBL] [Abstract][Full Text] [Related]
16. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
17. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
[TBL] [Abstract][Full Text] [Related]
18. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
20. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]